Science and Technology
Dual SMAD Inhibiting Proteins (DSIPs) are a group of ancient growth factors, conserved across species, that interfere with a cell’s ability to receive ligand-induced BMP and Activin programs. Our co-founders discovered their existence at Stanford University where they used state-of-the-art single cell technologies to understand why current drugs fail to cure breast cancer (Zabala, Lobo, Antony et al. Cell Stem Cell 2020).
Diseased cells abusively secrete DSIPs to continuously reprogram themselves to proliferate. Every disease has a unique DSIP expression profile.
Neutralizing DSIP activity is a totally new approach to treating diseases. In vivo experiments have validated Onena´s approach, proving that disruption of a DSIP’s activity with a neutralizing antibody reprograms cancer cells to accept environmental cell death signals from BMPs and Activins.
Cancer
Cancer
Each cancer type (colorectal, breast, lung, etc.) secretes a unique DSIP profile. An anti-DSIP neutralizing antibody given to a cancer patient reprograms the cancer cells, resulting in the cancer being extinguished.
Rare diseases
Rare Diseases
Some rare diseases are characterized by the uncontrolled growth of immature cells. An anti-DSIP antibody prevents the diseased immature cells from growing, resulting in healthy cells restoring normal tissue function.
Platform
Platform
Our proprietary platform connects artificially intelligent antibody design to functional DSIP neutralization. The result is a streamlined drug discovery process that quickly and cheaply identifies the best anti-DSIP antibody drugs.